when switching from semaglutide to tirzepatide switch dose from semaglutide to tirzepatide semaglutide tirzepatide dose conversion Equivalent
Description
Shares of UnitedHealth, which reported earnings that beat investor expectations, and CVS also were unchanged
While weight loss explained part of this effect, it did not account for everything
These results are better than those seen with approved dual agonists, making this peptide a possible best-in-class option for study into managing obesity
Clinical trials have shown average weight loss of up to 24.2% of total body weight over 48 weeks at the highest dose
[DOI] [PubMed] [Google Scholar] 531.Butler P.C., Meier J.J., Butler A.E., Bhushan A
